Recruiting PHASE2 INTERVENTIONAL 4-arm NCT07251998

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Patients With Moderate to Severe Plaque Psoriasis

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Conditions Plaque Psoriasis

Interventions ICP-332 Placebo Tablets ICP-332 Tablets

Updated 2 times since 2025 Last updated: Dec 24, 2025 Started: Dec 22, 2025 Primary completion: Oct 31, 2026 Completion: May 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07251998, this PHASE2 trial focuses on Plaque Psoriasis and remains actively recruiting participants. Sponsored by Beijing InnoCare Pharma Tech Co., Ltd., it has been updated 2 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

2 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing InnoCare Pharma Tech Co., Ltd.

Data source: Beijing InnoCare Pharma Tech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China